Top News

Jul 12, 2017
By Pharmaceutical Technology Editors
FDA advisory committee has recommended for approval Novartis CAR-T cell therapy CTL019 for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients.
Jul 11, 2017
By Pharmaceutical Technology Editors
The 2017 CPhI Pharma Awards program features 20 categories covering achievements in the pharma industry.
Jul 10, 2017
By Pharmaceutical Technology Editors
After FDA found a “significant shift in the route of abuse,” Endo voluntarily removes OPANA ER from the market.
Jul 05, 2017
By Pharmaceutical Technology Editors
The agency has pushed back by one year the deadline for compliance with DSCSA serialization requirements.
Jun 29, 2017
By Pharmaceutical Technology Editors
The agency announced a plan to eliminate its existing orphan designation request backlog.
Jun 20, 2017
By Pharmaceutical Technology Editors
Charlie Baker announced a plan to invest up to $500 million in the MA life-science industry.
Jun 12, 2017
The landmark decision determined that biosimilar makers can notify manufacturers before receiving FDA approval.
Jun 08, 2017
FDA asked Endo Pharmaceuticals to remove Opana ER from the market, citing the potential for abuse.
Jun 06, 2017
By Pharmaceutical Technology Editors
Yusef Manufacturing Laboratories, LLC received an FDA warning letter citing CGMP violations at its Clearfield, UT facility.
Jun 02, 2017
By Pharmaceutical Technology Editors
The company voluntarily recalled one lot of Brilinta 90 mg professional samples because it contained another medicine.
native1_300x100
lorem ipsum